Trials / Recruiting
RecruitingNCT05319314
GCC19CART for Patients With Metastatic Colorectal Cancer
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Lyell Immunopharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GCC19CART | Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.) |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2028-06-01
- Completion
- 2032-06-01
- First posted
- 2022-04-08
- Last updated
- 2026-02-27
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05319314. Inclusion in this directory is not an endorsement.